Form 4: Assembly Biosciences Officer Receives Significant Equity Grants

Assembly Biosciences officer Jeanette M. Bjorkquist was granted 300 restricted stock units and 600 stock options, aligning her compensation with the company's long-term performance.

Summary

• Jeanette M. Bjorkquist, an officer holding the titles of PFO and PAO at Assembly Biosciences, Inc. (ASMB), acquired 300 shares of Common Stock through a grant of restricted stock units (RSUs) on June 16, 2025.
• These RSUs are scheduled to vest in four equal annual installments, contingent on continuous service, on June 16, 2026, June 16, 2027, June 16, 2028, and June 16, 2029.
• Additionally, Ms. Bjorkquist was granted 600 stock options on June 16, 2025, with an exercise price of $17.24 per share and an expiration date of June 16, 2035.
• The stock options will vest over four years: 25% on the first anniversary of the grant (June 16, 2026), and the remaining 75% in 36 approximately equal monthly installments, achieving full vesting by June 16, 2029.
• Following these transactions, Ms. Bjorkquist's beneficial ownership includes 5,097 shares of Common Stock and 600 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of executive equity grants, which is a positive for aligning management incentives with shareholder interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units and stock options to a key officer (PFO and PAO) directly aligns management's long-term interests with those of shareholders.
• Equity-based compensation is a standard practice that incentivizes officers to contribute to the company's sustained growth and performance.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend through June 16, 2029, indicating an expectation of continued service from the officer and a long-term incentive structure tied to future company performance.

Industry Context

The granting of equity awards such as restricted stock units and stock options is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key executives. This practice aligns executive compensation with shareholder value creation and long-term company performance.

Comparison to Industry Standards

• The general mechanism of using RSUs and stock options for executive compensation is standard across the industry.
• Without access to Assembly Biosciences' full compensation policy or comparable compensation data from peer companies (e.g., other small to mid-cap biotech firms with similar development stages or market caps), a detailed quantitative comparison is not possible from this filing alone.
• The structure of multi-year vesting is typical for long-term incentive plans in the industry.

Related Party Transactions

• The reported transaction is an equity grant to an officer, which is a form of related party transaction (insider compensation) but is a standard part of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key officer with shareholders, potentially incentivizing long-term value creation.
• Employees: No direct impact on general employees is indicated, though it reflects the company's compensation philosophy for executives.

Next Steps

• Vesting of 25% of restricted stock units on June 16, 2026.
• Vesting of 25% of stock options on June 16, 2026.
• Subsequent annual vesting of restricted stock units through June 16, 2029.
• Subsequent monthly vesting of stock options through June 16, 2029.

Key Dates

Keywords

Assembly Biosciences, ASMB, Jeanette Bjorkquist, SEC Form 4, insider transaction, equity grant, restricted stock units, RSUs, stock options, executive compensation, beneficial ownership